Kan AI erstatte 60% af farmaceutisk F&U ved at designe og teste nye lægemidler in silico ved hjælp af generativ kemi og prædiktive toksicitetsmodeller ?
Afgiv din stemme — læs så hvad vores redaktør og AI-modellerne fandt.
Dybde læring-modeller som AlphaFold har allerede revolutioneret proteinfoldning. Generativ AI foreslår nu nye molekyler med lovende bindingsstyrker – hvilket rejser spørgsmålet om, hvornår AI fuldt ud kan overtage lægemiddelforskningen.
Background
As of 2024, AI-driven generative chemistry and predictive toxicity models have made significant strides in accelerating early-stage drug discovery, enabling rapid in silico design and screening of molecular candidates. Techniques such as multi-objective optimization with reinforcement learning (e.g., REINVENT or MolGen) and transformer-based models (e.g., AlphaFold2-informed docking) can propose novel structures with favorable binding affinities and reduced off-target risks. Deep learning models like AlphaFold have already revolutionized protein folding. However, no published source supports the claim that these tools can autonomously replace 60% of traditional pharmaceutical R&D—clinical trials, regulatory filings, and large-scale human trials remain human-led and data-intensive. Current industry practice emphasizes AI as a force multiplier in hit discovery and lead optimization rather than a wholesale replacement of R&D workflows.
Foreslå et tag
Mangler et begreb i dette emne? Foreslå det, admin gennemgår.
Status senest tjekket September 25, 2026.
Galleri
Kan AI erstatte 60% af farmaceutisk F&U ved at designe og teste nye lægemidler in silico ved hjælp af generativ kemi og prædiktive toksicitetsmodeller?
Snævre demoer findes — men panelet var ikke enigt.
But the data is real.
The Case File
Across 26 sessions, 55 jurors have heard this case. Combined tally: 0 YES · 49 ALMOST · 5 NO · 1 IN RESEARCH.
Note: cumulative includes older juror opinions. The current session tally above is the live verdict.
By a vote of 0 — 1 — 0, the panel returns a verdict of NæSTEN, with verdict confidence of 82%. The court so orders. Verdict upgraded from prior session.
"AI can generate candidates and predict toxicity in limited settings, but no system replaces the majority of pharma R&D at 60% scale."
Individuelle nævningers udtalelser vises på originalengelsk for at bevare bevismæssig præcision.
Hvad publikum mener
Nej 36% · Ja 24% · Måske 40% 25 votesDiskussion
no comments⚖ 26 jury checks · seneste for 1 dag siden
Hver række er et separat jurytjek. Nævninger er AI-modeller (identiteter holdt neutrale med vilje). Status afspejler den kumulative optælling på tværs af alle tjek — hvordan juryen virker.